In vivo targeting with bifuncitonal antibodies

Details In vivo targeting with bifuncitonal antibodies In vivo targeting with bifuncitonal antibodies

A - Human Necessities

61

K

A61K 39/395 (2006.01) A61K 47/48 (2006.01) A61K 49/00 (2006.01) C07K 16/46 (2006.01) G01N 33/574 (2006.01)

Patent

CA 2044908

X-7303 ABSTRACT This invention belongs to the field of immunology and provides a method for designing and constructing bispecific antibodies whose binding profiles are more desirable than those of the monospecific antibodies from which they were derived. The invention is exemplified in part by a bispecific antibody type that preferentially binds to some carcinomas and, at the same time, achieves a much decreased cross-reactivity with critical normal tissue as compared to the parent antibodies. The invention is not limited to cancer therapy, and its scope envisions the ability to selectively direct a wide variety of agents to particular sites in the body for an assortment of purposes while reducing the level of cross-reactivity to undesired locations.

Affiliated with

Also associated with

Rating

In vivo targeting with bifuncitonal antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with In vivo targeting with bifuncitonal antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and In vivo targeting with bifuncitonal antibodies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-2033804